Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Gross Margin (2020 - 2025)

Silence Therapeutics' Gross Margin history spans 6 years, with the latest figure at 64.71% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 2724.0% to 64.71% in Q4 2025 year-over-year; TTM through Dec 2025 was 64.3%, a 833.0% decrease, with the full-year FY2025 number at 61.54%, down 1116.0% from a year prior.
  • Gross Margin hit 64.71% in Q4 2025 for Silence Therapeutics, up from 59.75% in the prior quarter.
  • Over the last five years, Gross Margin for SLN hit a ceiling of 91.95% in Q4 2024 and a floor of 322.12% in Q2 2024.
  • Historically, Gross Margin has averaged 22.12% across 5 years, with a median of 46.84% in 2023.
  • Biggest five-year swings in Gross Margin: surged 1467318bps in 2021 and later plummeted -39103bps in 2024.
  • Tracing SLN's Gross Margin over 5 years: stood at 40.19% in 2021, then crashed by -53bps to 19.01% in 2022, then surged by 89bps to 35.87% in 2023, then skyrocketed by 156bps to 91.95% in 2024, then dropped by -30bps to 64.71% in 2025.
  • Business Quant data shows Gross Margin for SLN at 64.71% in Q4 2025, 59.75% in Q3 2025, and 69.5% in Q2 2025.